LL-37 vs KPV: What’s the Difference?
The main difference between LL-37 and KPV is mechanism: LL-37 is studied for antimicrobial peptide research — Disrupts microbial membranes directly and modulates immune cell signaling. KPV is studied for gut and skin inflammation research — Anti-inflammatory tripeptide derived from alpha-MSH.
Antimicrobial peptide vs anti-inflammatory melanocortin fragment.
Key differences between LL-37 and KPV
- •Mechanism: LL-37 — Disrupts microbial membranes directly and modulates immune cell signaling. KPV — Anti-inflammatory tripeptide derived from alpha-MSH.
- •Primary research focus: LL-37 is studied for antimicrobial peptide research; KPV is studied for gut and skin inflammation research.
- •Overlap: the two compounds share immune system & inflammation.
- •Discussion context: LL-37 is most often discussed alongside antimicrobial peptide research, while KPV centres on gut and skin inflammation research.
| Attribute | LL-37 Cathelicidin | KPV Lys-Pro-Val |
|---|---|---|
| Category | Immune System & Inflammation | Immune System & Inflammation |
| Best known for | Antimicrobial peptide research | Gut and skin inflammation research |
| Mechanism of action | Disrupts microbial membranes directly and modulates immune cell signaling. | Anti-inflammatory tripeptide derived from alpha-MSH. Calms systemic flare-ups, stabilizes intestinal barrier. |
| Human research | Not catalogued | Limited |
| Animal research | Not catalogued | Moderate |
| Mechanistic research | Not catalogued | Emerging |
| Study cadence cited | — | Daily |
| In plain English | LL-37 is your body's natural antibiotic. Researchers study it for chronic infections, biofilms, and conditions where antibiotics fail. | KPV is the anti-inflammation tripeptide. Researchers study it for gut conditions like IBD and inflammatory skin issues. |
| How it works | Disrupts microbial membranes directly and modulates immune cell signaling. | Suppresses NF-κB signaling and reduces inflammatory cytokine release. |
| Researchers study | Chronic infections, wound healing, biofilms, and autoimmune skin conditions. | Inflammatory bowel disease, ulcerative colitis, and inflammatory skin conditions. |
| Internet discussion | Discussed in chronic Lyme and biofilm contexts. | Popular in gut-health research circles. |
Mechanism and research evidence, side by side
How LL-37 and KPV differ at the receptor level, and how much published research currently supports each. Evidence ratings describe the depth of publicly available literature — they are not claims of safety or effectiveness.
KPV
Anti-inflammatory tripeptide derived from alpha-MSH. Calms systemic flare-ups, stabilizes intestinal barrier.
- Local growth-factor and angiogenic signalling
- Cell migration, matrix remodelling and inflammatory modulation
- Connective-tissue, gut-lining and wound-repair endpoints
- Human research
- Limited
- Animal research
- Moderate
- Mechanistic research
- Emerging
Inflammation, IBD/Crohn's research, skin conditions
LL-37
Antimicrobial peptide research
LL-37 is your body's natural antibiotic. Researchers study it for chronic infections, biofilms, and conditions where antibiotics fail.
Disrupts microbial membranes directly and modulates immune cell signaling.
Chronic infections, wound healing, biofilms, and autoimmune skin conditions.
Discussed in chronic Lyme and biofilm contexts.
LL-37 is a naturally occurring antimicrobial peptide researched for chronic infection and biofilm contexts.
KPV
Gut and skin inflammation research
KPV is the anti-inflammation tripeptide. Researchers study it for gut conditions like IBD and inflammatory skin issues.
Suppresses NF-κB signaling and reduces inflammatory cytokine release.
Inflammatory bowel disease, ulcerative colitis, and inflammatory skin conditions.
Popular in gut-health research circles.
KPV is a tripeptide derived from alpha-MSH researched for gut and skin inflammation.